Many of the industrialists profiled in the book are no longer riding the wave of success.
Leaders need to be ready to adapt to technological changes as quickly as possible, while they build the tech capabilities, Nadella said.
With the Jaypee acquisition, the Suraksha group, which made lenders an offer of Rs 7,736 crore, will be able to expand its footprint in north India after making inroads in Mumbai's real estate market over the past year. Sudhir Valia, the promoter, was a co-founder and executive director of India's biggest pharmaceutical firm, Sun Pharmaceuticals, and is a close relative of Dilip Shanghvi.
HR Guru Mayank Rautela offers practical advice.
In an unified effort, twelve I-League club owners and representatives have decided to launch the Indian Professional Football Clubs Association (IPFCA).
Isha is set to tie the knot with Anand Piramal this week.
The mid-cap universe - comprising firms that rank 101-250 in terms of m-cap - could see as many as 17 new stocks move out. Similarly, over half a dozen stocks could exit the large-cap universe, which is defined as the top 100 entities in terms of m-cap.
Vodafone Group Plc won the Indian cabinet's approval for its $1.6 billion deal to buy out minority partners in its unit in the country, Information and Broadcasting Minister Manish Tewari said on Thursday.
Samina Vaziralli, daughter of joint Managing Director M K Hamied, was inducted into the company management. Cipla joins the league of major companies such as Lupin, Wockhardt, Elder Pharma, Piramal Healthcare and JB Chemicals in this regard.
Mayank Rautela distils his 20-odd years of experience in human resources management to tell you how you can ace in your career.
One smells a rat when cases are settled for too small a price offered either by the highest bidder or the promoter -- within and outside the legal ambit of insolvency process, observes Tamal Bandyopadhyay.
Antacid Digene and pain drug Brufen have been among the top in their categories in India for decades. But not their manufacturer, Abbott.
There is a case for more stringent evaluation of CSR plans based on voluntary allocations, but a rule-based approach might be more effective.
Top 100 billionaires see their wealth rise 10%; top 20 account for half of total wealth of top 100.
Indian auto and pharma industries import several critical components and raw materials from China.
This time the targets were the colonial style bungalows in the southern tip of the country's financial capital.
The Drug Controller General of India (DCGI) has sought clarification from pharma majors Dr Reddy's Laboratories and Mumbai-based Piramal Healthcare, for allegedly sponsoring doctors for conferences.
Bigger companies are signing equity JVs with global investors.
The rupee's appreciation of 6.4 per cent against the dollar and 12 per cent against the euro is likely to hurt the first-quarter performance of the pharmaceutical sector, indicate a results' preview by broking houses.
The acquisition of the debt-laden Binani has catapulted Birla-owned UltraTech to the top spot in India, leaving it free to turn attention to overseas market
The Rs 1,500-crore (Rs 15 billion) ladies handbag market will see some major action this year, with luggage makers V.I.P and Samsonite contemplating entry soon.
Fortis Healthcare Chairman Malvinder Mohan Singh on Wednesday said it planned to launch an IPO for its diagnostics business unit, Super Religare Laboratories (SRL), in 2011. SRL had acquired the diagnostics business of Piramal Healthcare for Rs 600 crore in the first quarter of this financial year.
India's largest domestic drug maker, Cipla, sold its emergency contraceptive brand, i-pill, to Piramal Healthcare in a deal worth Rs 950 million
Mumbai's property markets, where prices earlier crossed Rs 1 lakh per sq. ft in South Mumbai, are seeing a 20-25 per cent markdown from last year's levels.
Leading Indian drug majors, such as Ranbaxy Laboratories, Dr Reddy's Laboratories, Piramal Healthcare and Wockhardt, are in-licensing popular products from overseas drug makers to boost their domestic sales.
Buoyed by 8.8 per cent growth of the Indian economy in the first quarter this fiscal, industry on Tuesday said the GDP may expand by around 9 per cent during 2010-11, but cautioned against certain weak areas like financial services.
After decades of hunt for fortune abroad, India's pharmaceutical companies now plan to strike gold in their own backyard. Large players from Ranbaxy to Dr Reddy's and Piramal Healthcare are all headed to rural India to boost their revenues.
Wishlist for new PM includes growth boosters, reining in inflation, faster project clearance and reversal of Land Acquisition Act
Some of the top indebted companies likely to face financial headwinds in the coming quarters include NTPC, PowerGrid, Tata Steel, Adani Power, JSW Steel, UPL, and Steel Authority of India. Together these 201 companies owed Rs 14.9 trillion to their lenders at the end of September 30, 2019, up 4.1 per cent year-on-year (YoY) during the first half of FY20.
HR Guru Mayank Rautela offers practical advice.
HR Guru Mayank Rautela offers practical advice.
Stringent regulatory norms and the financial impact of the global credit crisis on some research companies may hurt half a dozen molecules of Indian companies, such as Glenmark, Nicholas Piramal and Ranbaxy Laboratories, that are close to launch, experts and analysts said.
Firms like Abbot, Piramal and Bayer India have made their presence felt at KJ Somaiya Institute of Management Studies, Mumbai. Increasingly, pharma companies are finding it easier to recruit people from B-schools for jobs in marketing, human resources and finance.
The voluntary move comes a little more than a year after the Central Drugs Standard Control Organisation, the central authority that approves new drugs for marketing, had asked the drug makers to withdraw the 'combination drugs' as they are 'unnecessary' and may pose health hazards. The Drugs Controller General of India had banned 294 combination drugs sold under nearly 1,053 brand names from the market in June 2007.
An increasing number of companies are outsourcing superannuation, gratuity and leave encashment programmes of their employees to insurance companies.The trend that emerged two years ago has got a shot in the arm with SAIL, Nicholas Piramal, Vishakhapatnam Port asking insurers to manage their employees' retirement programmes.
United States Secretary of State Hillary Clinton on Saturday had a breakfast meeting with top honchos of India Inc at the iconic, sea-facing Taj Hotel in Mumbai. Amongst those from India Inc who were present at the meeting included Ratan Tata, chairman of Tata Group and Reliance Industries' Mukesh Ambani. Others present were the chiefs of India's two largest banks, O P Bhatt of State Bank and Chanda Kochhar of ICICI Bank, Swati Piramal and Sudha Murthy.
Assocham's first lady chief talks of the need to unleash new ideas and wonders why, when India has such politically powerful women, they're hardly to be seen in business.
Pharma majors are collaborating with foreign companies to develop newer drugs.
Glenmark plans to start selling its anti-diarrhoea drug, Crofelemer, by the first-half of 2010 across the globe, except in North America, Europe, Japan and China, the company said. The confidence to sell the drug ahead of its rivals comes as the Crofelemer's original developer, Napo Pharmaceutical Inc, recently entered into a tie-up with a US-based drug maker, Salyx, for selling the drug in the US market, paving the way for Glenmark to sell it in the rest of the world.
In May last year, Peninsula forayed into the hospitality sector with a joint venture with textile maker and real estate developer, Arrow Webtex. The JV planned to build hotels in Mumbai, Pune, Nagpur, Nasik and Kolhapur in Maharashtra. There were also plans to develop hotels in Ahmedabad, Surat, Jamnagar, Mundra port, Goa and Kerala.
